News Release Detail

Harmony Biosciences has announced the annual call for applications for its Progress at the Heart and Patients at the Heart programs, which provide funding support for community and nonprofit organizations nationwide developing innovative, patient-centric initiatives that drive meaningful change for individuals affected by rare neurological diseases. The opening of this year's application period coincides with "Rare Disease Week," a global awareness week honoring the 300 million people affected by rare diseases.

This year, Harmony is expanding Progress at the Heart to more comprehensively address a wide range of health disparities and inequities affecting the rare neurological disease community, which often hinder access to optimal treatment and care among medically underserved patients.

"Progress at the Heart demonstrates our commitment to catalyzing substantial change within the rare neurological disease community by addressing a wide range of disparities, including those related to race, ethnicity, gender, sexual orientation, education, income, and geographic location," said Cate McCanless, Chief Corporate Affairs Officer at Harmony Biosciences. “Through this program, we aim to support thoughtful solutions that drive tangible progress by accelerating research, advocacy, and education to ensure that all individuals receive the treatment and care that best suits their needs.”

Additionally, Patients at the Heart will encompass initiatives that help address the unique needs of individuals with rare neurological disorders experiencing excessive daytime sleepiness. It will also focus on individuals living with Fragile X syndrome, a rare condition characterized by intellectual and developmental challenges resulting from a mutation in the FMR1 gene, which is the leading known cause of both inherited intellectual disability and autism spectrum disorder.

"As a company dedicated to developing innovative treatments for these conditions, we deeply empathize with the challenges individuals and their loved ones face when it comes to effectively managing them. We are steadfast in our commitment to innovate and collaborate with communities and caregivers to bring new solutions aimed at empowering people living with rare neurological disorders and their families to live their lives to the fullest," McCanless emphasized.

Applications for both funding programs will be accepted from February 26 to May 24. Organizations are encouraged to visit the Progress at the Heart and Patients at the Heart sections of our website for details and to submit applications.

About Progress at the Heart
Harmony Biosciences’ Progress at the Heart program supports novel initiatives addressing disparities and inequities in access to treatment and care in the rare neurological disease community. Applications and submission details can be accessed at: https://www.harmonybiosciences.com/funding-programs/progress-at-the-heart/.

About Patients at the Heart
Harmony Biosciences' Patients at the Heart program underscores our commitment to supporting initiatives that help address the unique needs of individuals with rare neurological disorders experiencing excessive daytime sleepiness, as well as individuals living with Fragile X syndrome. Applications and submission details can be accessed at: https://www.harmonybiosciences.com/funding-programs/patients-at-the-heart/.

About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.